Sumitomo Dainippon Pharma Logo
JP3495000006
858257
DNPUF

Sumitomo Dainippon Pharma

Loading quotes...

Forecast

There is no analyst data available for this company.

Discussions in the community

There is no discussion about this asset yet.

Start discussion

Historical dividends Dividends

All dividend metrics All metrics
In 2023, Sumitomo Dainippon Pharma has already paid €0.0444 in dividends. The last payout was in June 2023.

Financials

In the last quarter, Sumitomo Dainippon Pharma had revenue of €767.62M and net profit of €119.02M
(EUR) September 2026
YoY
Revenue 767.62M 11.92%
Gross profit 419.6M 0.89%
Net profit 119.02M 76.42%
EBITDA 156.65M 68.42%

Fundamentals

Metric Value
Market capitalization
€5.18B
Number of shares
448.59M
52-week high/low
€18.71 - €6.76
Dividends No
Beta
0.47
P/E ratio
19.02
PEG ratio
-0.26
P/B ratio
2.11
P/S ratio
1.85

Company profile

Sumitomo Pharma Co., Ltd. manufactures and sells pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally. The company offers pharmaceutical products, such as therapeutic agents for Parkinson's disease, depression, type 2 diabetes, systemic fungal infection, hypertension, pruritus, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It also provides products for atypical antipsychotic, antiepileptic, carbapenem antibiotic, and gastrointestinal; and Anderson-Fabry disease drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, as well as seasonings, such as soups or bouillons; and chemical product materials, which include pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials. Further, it provides veterinary medicines for companion animals, such as dogs and cats; and livestock comprising cattle, swine, poultry, horses, and aquacultured fish. Sumitomo Pharma Co., Ltd. has partnerships with Healios K.K.; Keio University; RIKEN; the Center for iPS Cell Research and Application; Kyoto University; and Aikomi Co., Ltd., as well as a joint development agreement with SanBio Company Limited; and collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. It also has a strategic alliance with Roivant Sciences Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was founded in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.

Name
Sumitomo Dainippon Pharma
CEO
Toru Kimura
Headquarters Osaka, os
Japan
Website
IPO
01/04/2000
Employees 3,123

Ticker symbols

Exchange Symbol
Pnk
DNPUF
Japan Exchange Group
4506.T
Frankfurt
DPM.F
Düsseldorf
DPM.DU
München
DPM.MU
🍪

Parqet  uses cookies. Learn more